Genmab — August 2017
-
Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT03236428?term=daratumumab&lup_s=07%2F31%2F2017&rank=1 http://www.bioportfolio.com/resources/trial/185503/Study-of-the-CD38-Antibody-Daratumumab-in-Patients-With-High-Risk-MGUS.html
-
Ocrevus solgte for 200M USD i første kvartal på markedet. GSK har været et dyrt bekendtskab for genmab, nu må vi håbe der er er et marked om 2-3år, når sc ofa er klar.
-
God morgen.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
